ZymoGenetics Sales Chief Exits
Luke Timmerman2/4/09
ZymoGenetics’ senior vice president of sales and marketing, Michael Dwyer, has left the company as of yesterday, according to a regulatory filing. The Seattle-based company (NASDAQ: ZGEN) didn’t explain why he left, or financial terms of his departure. Dwyer joined the company in April 2006 to commercialize its first FDA-approved drug, recombinant thrombin (Recothrom). The drug has gotten off to a slow start, generating an estimated $7 million in U.S. sales in 2008.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
